# Sitting on a Cash Pile 13.0? This Bio-Tech is Focused on Discovering and Developing Cancer Immunotherapies Live Trading News is an independent financial media publication. Masthead: Live Trading News. Parent: Knightsbridge Group. Product cousin: KXCO (kxco.ai). Coverage: markets, policy, AI, quantum, blockchain, FX, biotech, ASEAN. New stories are signed ML-DSA-65 and anchored on Armature L1; articles published before the platform launch are not signed. Nothing on the site is investment advice. Canonical HTML: https://www.livetradingnews.com/sitting-on-a-cash-pile-13-0-this-bio-tech-is-focused-on-discovering-and-developing-cancer-immunotherapies Last modified: 2021-03-31 --- By Paul Ebeling · 2021-03-31 Tags: Shayne Heffernan on Investments, buy, cancer, cash, support, Bullish, Headline News, Paul Ebeling, lymphoma, Todays Trade Ideas, 2021, AFMD, immunotherapies, Hodgkin Signed: no (published before platform launch). Nothing in this article is investment advice. [#cash](https://www.livetradingnews.com/tag/cash) [#bullish](https://www.livetradingnews.com/tag/bullish) [#buy](https://www.livetradingnews.com/tag/buy) [$AFMD ](https://finance.yahoo.com/quote/AFMD?p=AFMD&.tsrc=fin-srch) Affimed NV ([NASDAQ:AFMD](NASDAQ:AFMD)) broke out on 10 March at 6.88 and confirmed on 31 March at 7.91. Thus, garnering a LTN Cash Pile Buy rating with a 1 yr price target at 12.54. The Street's consensus target is at 12.36. AFMD closed Wednesday at 7.91 within 52-wk range of 1.50 - 8.60. The Key support is at 7.63 and the resistance is Nil beyond 8.48. Our outlook is Bullish with a Very Bullish bias in here, as the Fibo technical indicator tuned Very Bullish Wednesday. ![](https://livetradingnews-media.nyc3.digitaloceanspaces.com/wp/placeholder.svg) Affimed NV is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Corporation; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. and Roche. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; Genentech; and Roivant Sciences. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed NV in October 2014. Affimed N.V. was founded in Y 2000 and is HQ'd in Heidelberg, Germany Have a healthy day, Keep the Faith! --- This Markdown mirrors https://www.livetradingnews.com/sitting-on-a-cash-pile-13-0-this-bio-tech-is-focused-on-discovering-and-developing-cancer-immunotherapies. The HTML page is canonical. Site index for AI clients: https://www.livetradingnews.com/llms.txt